Rapamycin

Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].

Product Specifications

CAS Number

[53123-88-9]

Product Name Alternative

Sirolimus; AY-22989; NSC 226080

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR

Type

Natural Products

Related Pathways

Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection; Neurological Disease; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Rapamycin.html

Purity

99.94

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O

Molecular Formula

C51H79NO13

Molecular Weight

914.17

Precautions

H302, H315, H319, H335

References & Citations

[1]Edwards SR, et al. The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem, 2007, 282 (18), 13395-13401.|[2]Rangaraju S, et al. Rapamycin activates autophagy and improves myelination in explant cultures from neuropathicmice. J Neurosci. 2010 Aug 25;30 (34) :11388-97.|[3]Niu H, et al. Rapamycin potentiates cytotoxicity by RP-56976 possibly through downregulation of Survivin in lung cancer cells. J Exp Clin Cancer Res. 2011 Mar 10;30:28.|[4]Zhang JW, et al. Metformin synergizes with rapamycin to inhibit the growth of pancreatic cancer in vitro and in vivo. Oncol Lett. 2018 Feb;15 (2) :1811-1816.